Compare RGNX & HELP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RGNX | HELP |
|---|---|---|
| Founded | 2008 | 2019 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 793.5M | 862.2M |
| IPO Year | 2015 | 2020 |
| Metric | RGNX | HELP |
|---|---|---|
| Price | $7.45 | $11.12 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 11 |
| Target Price | $23.58 | ★ $41.40 |
| AVG Volume (30 Days) | 1.3M | ★ 1.4M |
| Earning Date | 11-09-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 18.08 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $10,393,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $23.50 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 126.48 | N/A |
| 52 Week Low | $5.46 | $3.76 |
| 52 Week High | $16.19 | $15.15 |
| Indicator | RGNX | HELP |
|---|---|---|
| Relative Strength Index (RSI) | 50.22 | 50.01 |
| Support Level | $6.96 | $4.41 |
| Resistance Level | $8.31 | $11.74 |
| Average True Range (ATR) | 0.43 | 0.89 |
| MACD | 0.06 | 0.06 |
| Stochastic Oscillator | 55.77 | 47.35 |
Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.
Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.